Who are Albumin-bound Paclitaxel plus S-1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Taxane plus Intermittent Capecitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/albumin-bound-paclitaxel-plus-s-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Albumin-bound Paclitaxel plus S-1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Albumin-bound Paclitaxel plus S-1 (Albumin-bound Paclitaxel plus S-1) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy (taxane + fluoropyrimidine). Area: Oncology.

phase 3 Combination chemotherapy (taxane + fluoropyrimidine) Microtubules (paclitaxel); Thymidylate synthase (S-1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Albumin-bound Paclitaxel plus S-1 (Albumin-bound Paclitaxel plus S-1) — Huazhong University of Science and Technology. Albumin-bound paclitaxel inhibits microtubule depolymerization to arrest cell cycle, while S-1 (tegafur/gimeracil/oteracil) inhibits thymidylate synthase to disrupt DNA synthesis, together providing synergistic cytotoxic effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Albumin-bound Paclitaxel plus S-1 TARGET	Albumin-bound Paclitaxel plus S-1	Huazhong University of Science and Technology	phase 3	Combination chemotherapy (taxane + fluoropyrimidine)	Microtubules (paclitaxel); Thymidylate synthase (S-1)
Taxane plus Intermittent Capecitabine	Taxane plus Intermittent Capecitabine	Sun Yat-sen University	phase 3	Combination chemotherapy (taxane + fluoropyrimidine)	Microtubules (taxane); thymidylate synthase (capecitabine/5-FU)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy (taxane + fluoropyrimidine) class)

Huazhong University of Science and Technology · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Albumin-bound Paclitaxel plus S-1 — Competitive Intelligence Brief. https://druglandscape.com/ci/albumin-bound-paclitaxel-plus-s-1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab